Request Trial
preto-perola-shutterstock-com-1
Preto Perola / Shutterstock.com
12 November 2015PharmaDuncan Ribbons and Maeve Lynch

CRISPR: the shifting sands of patentability

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9) technology is a revolutionary method of modifying genomic sequences. Although genomic modification has been possible for many years, CRISPR technology is cheaper, easier and more accurate than the modification tools preceding it.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Lilly mounts defence as generics circle Mounjaro and Zepbound
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

More features

Invisalign maker secures first China win against clear aligner rival
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
Lilly mounts defence as generics circle Mounjaro and Zepbound
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
The UPC plugs another gap in its procedural rulebook
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
Patent litigator joins Baker Botts in London as UPC grows in significance